Canopy Growth Corp vs W W Grainger Inc — how do they compare? Canopy Growth Corp trades at $0.96 (market cap $398.46M), while W W Grainger Inc trades at $1,365.2 (market cap $64.73B). The key difference: W W Grainger Inc is far larger — about 162.5× Canopy Growth Corp's market cap, and W W Grainger Inc pays a 0.68% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | GWW | |
|---|---|---|
Market Cap | $398.46M | $64.73B |
Sector | Health | Technology |
52-Week High | $1.92 | $1.39K |
52-Week Low | $0.86 | $918.18 |
Enterprise Value | $337.90M | $66.82B |
Dividend Yield | — | 0.68% |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
GWW trades at $1,391.68, up 1.16% today, with a bullish technical outlook supported by moving averages and strong momentum. The company reported Q1 2026 EPS of $11.65, beating estimates, and raised its full-year guidance. Revenue growth remains steady, with 2026 revenue projected at $18.4B, while profitability metrics like ROE of 48.1% and net margin near 10% highlight operational strength. Positive analyst sentiment and recent dividend declarations reinforce investor confidence amid a favorable market backdrop.
The outlook for GWW is positive, driven by earnings beats and raised guidance, though valuation multiples like a P/E of 36.87 suggest premium pricing. Risks include economic sensitivity and competitive pressures, but institutional buy ratings and technical support near $1,380 provide a cushion for upward momentum if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →